The DOI matches its Crossref record; 529 of the 529 references it cites were found in a registry or an index.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Abstract
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Self-citationClozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.975 · Cited by 1,593
The Cochrane Database of Systematic Reviews
Handoll, H. H. (2004) · The British Journal of Hand Therapy · doi:10.1177/175899830400900201 · Cited by 1,513
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,348
Perkins, D. O., Gu, H., Boteva, K., & Lieberman, J. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1785 · Cited by 1,346
Self-citationSecond-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Comprehensive Textbook of Psychiatry
Schwab, J. J. (1968) · Psychosomatics · doi:10.1016/s0033-3182(68)71813-2 · Cited by 1,294
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., Laughren, T. P., & Katz, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Self-citationDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · cited 2×
“…jointly by the European Psychiatric Association together with the European Society of Cardiology and the European Association for the Study of Diabetes included an algorithm for the risk management of cardiovascular disease and diabetes in patients with severe mental illness (De Hert et al. 2009).”
BackgroundSelf-citationThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Self-citationImpaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With Schizophrenia
Ryan, M. C. M., Collins, P., & Thakore, J. H. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.284 · Cited by 828
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Self-citationArvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
One hundred years of schizophrenia: a meta-analysis of the outcome literature
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.10.1409 · Cited by 762
Marder, S. R., Davis, J. M., & Chouinard, G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1205 · Cited by 759
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003
Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 757
Practice Guideline for the Treatment of Patients With Schizophrenia Second Edition
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.45859 · Cited by 737
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
What Clinicians Should Know About the QT Interval
Al-Khatib, S. M., LaPointe, N. M. A., Kramer, J. M., & Califf, R. M. (2003) · JAMA · doi:10.1001/jama.289.16.2120 · Cited by 667
Chakos, M., Lieberman, J., Hoffman, E., Bradford, D., & Sheitman, B. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.518 · Cited by 631
Self-citationKane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
Reilly, J., Ayis, S., Ferrier, I., Jones, S., & Thomas, S. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02035-3 · Cited by 602
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
Neuroleptic Malignant Syndrome
Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.870 · Cited by 579
Peuskens, J. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.6.712 · Cited by 551
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Self-citationAlper, K., Schwartz, K. A., Kolts, R. L., & Khan, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.023 · Cited by 522
Treatment of Negative Symptoms
Carpenter, W. T., Heinrichs, D. W., & Alphs, L. D. (1985) · Schizophrenia Bulletin · doi:10.1093/schbul/11.3.440 · Cited by 499
The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009
Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp130 · Cited by 499
Leucht, S., Komossa, K., Rummel-Kluge, C., Corves, C., Hunger, H., Schmid, F., Asenjo Lobos, C., Schwarz, S., & Davis, J. M. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030368 · Cited by 490
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Quetiapine in Patients With Schizophrenia: A High- and Low-Dose Double-blind Comparison With Placebo
Small, J. G. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830180067009 · Cited by 478
Amisulpride, an Unusual “Atypical” Antipsychotic: A Meta-Analysis of Randomized Controlled Trials
Leucht, S., Pitschel-Walz, G., Engel, R. R., & Kissling, W. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.180 · Cited by 470
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Royal Australian And New Zealand College Of Psychiatrists Clinical Practice Guidelines Team For The Treatment Of Schizophrenia And Related Disorders (2005) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/j.1440-1614.2005.01516.x · Cited by 435
Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death
Haddad, P. M., & Anderson, I. M. (2002) · Drugs · doi:10.2165/00003495-200262110-00006 · Cited by 435
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
Overview: maintenance therapy in psychiatry: I. Schizophrenia
(1975) · American Journal of Psychiatry · doi:10.1176/ajp.132.12.1237 · Cited by 410
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Self-citationLieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
Self-citationCorrell, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S. (1996) · Psychopharmacology · doi:10.1007/bf02245617 · Cited by 390
Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.1.20 · Cited by 388
(2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0219 · Cited by 383
McEvoy, J. P. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320063009 · Cited by 381
Daniel, D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00090-6 · Cited by 377
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
Harrigan, E. P., Miceli, J. J., Anziano, R., Watsky, E., Reeves, K. R., Cutler, N. R., Sramek, J., Shiovitz, T., & Middle, M. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104913.75206.62 · Cited by 363
Dose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 358
Wahlbeck, K., Cheine, M., Essali, A., & Adams, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.990 · Cited by 357
Electroconvulsive therapy for schizophrenia
Tharyan, P., & Adams, C. E. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000076.pub2 · Cited by 354
Management of treatment resistance in schizophrenia
Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352
Battaglia, J., Moss, S., Rush, J., Kang, J., Mendoza, R., Leedom, L., Dubin, W., McGlynn, C., & Goodman, L. (1997) · The American Journal of Emergency Medicine · doi:10.1016/s0735-6757(97)90119-4 · Cited by 350
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationLieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Self-citationConley, R. R., & Mahmoud, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 334
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Self-citationConn, P. J., Lindsley, C. W., & Jones, C. K. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330
Clozapine versus typical neuroleptic medication for schizophrenia
Essali, A., Al-Haj Haasan, N., Li, C., & Rathbone, J. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000059.pub2 · Cited by 329
Rosenheck, R. (2003) · JAMA · doi:10.1001/jama.290.20.2693 · Cited by 326
Kane (2003) · The Journal of Clinical Psychiatry · Cited by 323
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.231 · Cited by 322
Devinsky, O., Honigfeld, G., & Patin, J. (1991) · Neurology · doi:10.1212/wnl.41.3.369 · Cited by 322
Davidson, M., Galderisi, S., Weiser, M., Werbeloff, N., Fleischhacker, W. W., Keefe, R. S., Boter, H., Keet, I. P. M., Prelipceanu, D., Rybakowski, J. K., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08060806 · Cited by 320
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, A. E., Hayden, D., Weber, M. T., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 319
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Self-citationStructural Evaluation of the Prefrontal Cortex in Schizophrenia
Buchanan, R. W., Vladar, K., Barta, P. E., & Pearlson, G. D. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.8.1049 · Cited by 314
Kasper, S., Lerman, M. N., McQuade, R. D., Saha, A., Carson, W. H., Ali, M., Archibald, D., Ingenito, G., Marcus, R., & Pigott, T. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309
Antipsychotic Drugs: A New Risk Factor for Osteoporosis in Young Women With Schizophrenia?
O'Keane, V., & Meaney, A. M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000150223.31007.e0 · Cited by 307
Prolactin Levels and Adverse Events in Patients Treated with Risperidone
Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00011 · Cited by 307
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.466 · Cited by 305
Wright, P., Birkett, M., David, S. R., Meehan, K., Ferchland, I., Alaka, K. J., Saunders, J. C., Krueger, J., Bradley, P., San, L., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1149 · Cited by 303
KANE, J., CANAS, F., KRAMER, M., FORD, L., GASSMANNMAYER, C., LIM, P., & EERDEKENS, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.012 · Cited by 296
Claus, A., Bollen, J., Cuyper, H. D., Eneman, M., Malfroid, M., Peuskens, J., & Heylen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb01473.x · Cited by 295
Breier, A., Meehan, K., Birkett, M., David, S., Ferchland, I., Sutton, V., Taylor, C. C., Palmer, R., Dossenbach, M., Kiesler, G., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.5.441 · Cited by 289
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update
Moore, T. A., & Buchanan, R. W. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1115 · Cited by 288
Metabolic syndrome and mental illness.
Newcomer, J. W. (2007) · PubMed · Cited by 285
Bondolfi, G., Dufour, H., Patris, M., May, J. P., Billeter, U., Eap, C. B., & Baumann, P. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.4.499 · Cited by 283
(2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 282
Rosenheck, R. A., Leslie, D. L., Sindelar, J., Miller, E. A., Lin, H., Stroup, T. S., McEvoy, J., Davis, S. M., Keefe, R. S. E., Swartz, M., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2080 · Cited by 281
Self-citationClozapine alone versus clozapine and risperidone with refractory schizophrenia
Honer, W. G., Thornton, A. E., Chen, E. Y. H., Chan, R. C. K., Wong, J. O. Y., Bergmann, A., Falkai, P., Pomarol-Clotet, E., McKenna, P. J., Stip, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053222 · Cited by 277
Self-citationKeefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1061 · Cited by 276
Self-citationTandon, R., Belmaker, R. H., Gattaz, W. F., Lopez-Ibor, J. J., Okasha, A., Singh, B., Stein, D. J., Olie, J.-P., Fleischhacker, W. W., & Moeller, H.-J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.11.033 · Cited by 276
Self-citationSmith, M., Hopkins, D., Peveler, R. C., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 275
Psychopharmacologic Treatment of Schizophrenia
Kane, J. M., & Marder, S. R. (1993) · Schizophrenia Bulletin · doi:10.1093/schbul/19.2.287 · Cited by 273
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Kissling, W., Davis, J. M., & Leucht, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq042 · Cited by 272
Meltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Neuroleptics: Effects on Neuropsychological Function in Chronic Schizophrenic Patients
Cassens, G., Inglis, A. K., Appelbaum, P. S., & Gutheil, T. G. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.3.477 · Cited by 271
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Self-citationBorison, R. L., Arvanitis, L. A., & Milier, B. G. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199604000-00008 · Cited by 268
Extrapyramidal side-effects of antipsychotics in a randomised trial
Miller, D. D., Caroff, S. N., Davis, S. M., Rosenheck, R. A., McEvoy, J. P., Saltz, B. L., Riggio, S., Chakos, M. H., Swartz, M. S., Keefe, R. S. E., et al. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.050088 · Cited by 265
Self-citationKeck Jr, P., Buffenstein, A., Ferguson, J., Feighner, J., Jaffe, W., Harrigan, E. P., & Morrissey, M. R. (1998) · Psychopharmacology · doi:10.1007/s002130050755 · Cited by 265
Buchanan, R. W., Breier, A., Kirkpatrick, B., Ball, P., & Carpenter, W. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.751 · Cited by 264
Quetiapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Schmid, F., Hunger, H., Schwarz, S., Srisurapanont, M., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006625.pub2 · Cited by 260
Shiloh, R., Zemishlany, Z., Aizenberg, D., Radwan, M., Schwartz, B., Dorfman-Etrog, P., Modai, I., Khaikin, M., & Weizman, A. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.569 · Cited by 260
Freudenreich, O., & Goff, D. C. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.01331.x · Cited by 259
Paliperidone for schizophrenia
Dolder, C., Nelson, M., & Deyo, Z. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070261 · Cited by 254
Topiramate and Psychiatric Adverse Events in Patients with Epilepsy
Mula, M., Trimble, M. R., Lhatoo, S. D., & Sander, J. W. A. S. (2003) · Epilepsia · doi:10.1046/j.1528-1157.2003.05402.x · Cited by 254
Freitas, C., Fregni, F., & Pascual-Leone, A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.11.027 · Cited by 251
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
Peuskens, J., & Link, C. G. G. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb10162.x · Cited by 251
Kane, J. M., Lauriello, J., Laska, E., Di Marino, M., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318169cca7 · Cited by 250
Meltzer, H. Y., Cucchiaro, J., Silva, R., Ogasa, M., Phillips, D., Xu, J., Kalali, A. H., Schweizer, E., Pikalov, A., & Loebel, A. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10060907 · Cited by 250
Davidson, M., Emsley, R., Kramer, M., Ford, L., Pan, G., Lim, P., & Eerdekens, M. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.03.003 · Cited by 249
Aleman, A., Sommer, I. E., & Kahn, R. S. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0310 · Cited by 247
At Issue: Defining Treatment Refractoriness in Schizophrenia
Brenner, H. D., Dencker, S. J., Goldstein, M. J., Hubbard, J. W., Keegan, D. L., Kruger, G., Kulhanek, F., Liberman, R. P., Malm, U., & Midha, K. K. (1990) · Schizophrenia Bulletin · doi:10.1093/schbul/16.4.551 · Cited by 242
Neuroleptic Malignant Syndrome: A Review
Pelonero, A. L., Levenson, J. L., & Pandurangi, A. K. (1998) · Psychiatric Services · doi:10.1176/ps.49.9.1163 · Cited by 241
Ziprasidone versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Bhoopathi, P. S., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006627.pub2 · Cited by 240
Evaluation of Treatment-Resistant Schizophrenia
Conley, R. R., & Buchanan, R. W. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.663 · Cited by 238
Duggan, L., Fenton, M., Rathbone, J., Dardennes, R., El-Dosoky, A., & Indran, S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001359.pub2 · Cited by 237
Arterial Stiffness and Stroke in Hypertension: Therapeutic Implications for Stroke Prevention
Laurent, S., & Boutouyrie, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00001 · Cited by 236
The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2003 Update
Miller, A. L., Hall, C. S., Buchanan, R. W., Buckley, P. F., Chiles, J. A., Conley, R. R., Crismon, M. L., Ereshefsky, L., Essock, S. M., Finnerty, M., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0408 · Cited by 234
Josiassen, R. C., Joseph, A., Kohegyi, E., Stokes, S., Dadvand, M., Paing, W. W., & Shaughnessy, R. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.130 · Cited by 233
Does switching to a new antipsychotic improve outcomes?
Rosenheck, R. A., Davis, S., Covell, N., Essock, S., Swartz, M., Stroup, S., McEvoy, J., & Lieberman, J. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.031 · Cited by 232
Self-citationCasey, D. E., Daniel, D. G., Wassef, A. A., Tracy, K. A., Wozniak, P., & Sommerville, K. W. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300023 · Cited by 232
Aripiprazole for schizophrenia
El-Sayeh, H. G., & Morganti, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004578.pub3 · Cited by 230
Marder, S. R., Kramer, M., Ford, L., Eerdekens, E., Lim, P., Eerdekens, M., & Lowy, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.017 · Cited by 229
Treatment of Negative Symptoms in Schizophrenia with Amisulpride
Boyer, P., Lecrubier, Y., Puech, A. J., Dewailly, J., & Aubin, F. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.166.1.68 · Cited by 229
Ganguly, R., Kotzan, J. A., Miller, L. S., Kennedy, K., & Martin, B. C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1013 · Cited by 227
Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., DeThomas, C., Kafantaris, V., Correll, C. U., & Kane, J. M. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.043 · Cited by 223
Singh, S. P., Singh, V., Kar, N., & Chan, K. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067710 · Cited by 223
Benzodiazepines in the treatment of schizophrenia: a review and reappraisal
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.714 · Cited by 221
Clozapine in treatment-resistant schizophrenics.
Kane, J. M., Honigfeld, G., Singer, J., & Meltzer, H. Y. (1988) · PubMed · Cited by 217
Olanzapine Versus Haloperidol Treatment in First-Episode Psychosis
Sanger, T. M., Lieberman, J. A., Tohen, M., Grundy, S., Beasley, Jr., & Tollefson, G. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.79 · Cited by 215
Self-citationSexual dysfunction in male schizophrenic patients.
Aizenberg, D., Zemishlany, Z., Dorfman-Etrog, P., & Weizman, A. (1995) · PubMed · Cited by 213
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
Bushe, C., & Holt, R. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.47.s67 · Cited by 212
Risperidone: clinical safety and efficacy in schizophrenia.
Borison, R. L., Pathiraja, A., Diamond, B. I., & Meibach, R. C. (1992) · PubMed · Cited by 210
Breier, A. F., Malhotra, A. K., Su, T.-P., Pinals, D. A., Elman, I., Adler, C. M., Lafargue, R. T., Clifton, A., & Pickar, D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.294 · Cited by 208
Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.179 · Cited by 207
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 207
Self-citationHaloperidol versus chlorpromazine for schizophrenia
Leucht, C., Kitzmantel, M., Kane, J., Leucht, S., & Chua, W. L. L. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004278.pub2 · Cited by 206
Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia.
Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K., & Gerber, B. (1994) · PubMed · Cited by 206
Amisulpride versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Silveira da Mota Neto, J. I., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006624.pub2 · Cited by 205
Tollefson, G. D., Birkett, M. A., Kiesler, G. M., & Wood, A. J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01026-x · Cited by 202
Clozapine‐related seizures: Experience with 5,629 patients
Pacia, S. V., & Devinsky, O. (1994) · Neurology · doi:10.1212/wnl.44.12.2247 · Cited by 199
Fleischhacker, W. W., Heikkinen, M. E., Olié, J.-P., Landsberg, W., Dewaele, P., McQuade, R. D., Loze, J.-Y., Hennicken, D., & Kerselaers, W. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000490 · Cited by 198
Helgason, L. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb06486.x · Cited by 196
Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia
Loo, H., Poirier-Littre, M.-F., Theron, M., Rein, W., & Fleurot, O. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.1.18 · Cited by 195
Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks
Barnes, T. R. E., & Paton, C. (2011) · CNS Drugs · doi:10.2165/11587810-000000000-00000 · Cited by 194
Tiihonen, J., Wahlbeck, K., & Kiviniemi, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.01.002 · Cited by 194
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
VanderZwaag, C. J., McGee, M., McEvoy, J. P., Freudenreich, O., Wilson, W. H., & Cooper, T. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1579 · Cited by 193
Chang, J. S., Ahn, Y. M., Park, H. J., Lee, K. Y., Kim, S. H., Kang, U. G., & Kim, Y. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0505 · Cited by 192
Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Tiihonen, J., Hallikainen, T., Ryynänen, O.-P., Repo-Tiihonen, E., Kotilainen, I., Eronen, M., Toivonen, P., Wahlbeck, K., & Putkonen, A. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00524-9 · Cited by 191
Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial
Nakamura, M., Ogasa, M., Guarino, J., Phillips, D., Severs, J., Cucchiaro, J., & Loebel, A. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04905 · Cited by 191
Zuclopenthixol acetate in the treatment of acute schizophrenia and similar serious mental illnesses
Fenton, M., Coutinho, E., & Campbell, C. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000525 · Cited by 190
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.133 · Cited by 190
Hasegawa, M., Gutierrez-Esteinou, R., Way, L. E., & Meltzer, H. Y. (1993) · PubMed · Cited by 189
Clark, R. E., Bartels, S. J., Mellman, T. A., & Peacock, W. J. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006928 · Cited by 189
The pharmacology of weight gain with antipsychotics.
Casey, D. E., & Zorn, S. H. (2001) · PubMed · Cited by 187
Principles and practice of psychopharmacotherapy
Janicak, P. G. (2001) · Cited by 187
Antipsychotic medication and seizures: A review
Hedges, D., Jeppson, K., & Whitehead, P. (2003) · Drugs of Today · doi:10.1358/dot.2003.39.7.799445 · Cited by 185
Yagcioglu, A. E. A., Akdede, B. B. K., Turgut, T. I., Tümüklü, M., Yazici, M. K., Alptekin, K., Ertugrul, A., Jayathilake, K., Gögüs, A., Tunca, Z., et al. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0109 · Cited by 185
Improvement of Schizophrenic Patients With Primary Negative Symptoms Treated With Amisulpride
Danion, J.-M., Rein, W., Fleurot, O., & the Amisulpride Study Group (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.4.610 · Cited by 185
Risperidone versus typical antipsychotic medication for schizophrenia
Hunter, R., Kennedy, E., Song, F., Gadon, L., & Irving, C. B. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000440 · Cited by 183
Wang, Y., Xia, J., Helfer, B., Li, C., & Leucht, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004028.pub4 · Cited by 183
Goff, D. C., Posever, T., Herz, L., Simmons, J., Kletti, N., Lapierre, K., Wilner, K. D., Law, C. G., & Ko, G. N. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199808000-00009 · Cited by 183
Sertindole versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schwarz, S., Schmid, F., Lewis, R., Kissling, W., & Leucht, S. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006752.pub2 · Cited by 183
Does cognitive function improve with quetiapine in comparison to haloperidol?
Velligan, D. I., Newcomer, J., Pultz, J., Csernansky, J., Hoff, A. L., Mahurin, R., & Miller, A. L. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00268-7 · Cited by 183
Sommer, I. E., de Witte, L., Begemann, M., & Kahn, R. S. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06823 · Cited by 182
Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study
Ungvari, G. S., Chiu, H. F. K., Chow, L. Y., Lau, B. S. T., & Tang, W. K. (1999) · Psychopharmacology · doi:10.1007/s002130050904 · Cited by 182
The Pharmacology and Toxicology of Atypical Antipsychotic Agents
Burns, M. J. (2001) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-100102873 · Cited by 181
Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study
Emsley, R. A., & Risperidone Working Group (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033413 · Cited by 180
Conventional Antipsychotic Medications for Schizophrenia
Dixon, L. B., Lehman, A. F., & Levine, J. (1995) · Schizophrenia Bulletin · doi:10.1093/schbul/21.4.567 · Cited by 180
Effectiveness of Switching From Antipsychotic Polypharmacy to Monotherapy
Essock, S. M., Schooler, N. R., Stroup, T. S., McEvoy, J. P., Rojas, I., Jackson, C., Covell, N. H., & The Schizophrenia Trials Network (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10060908 · Cited by 179
Azorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179
Arato, M., O??Connor, R., & Meltzer, H. Y. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00001 · Cited by 178
Kane, J. M., Marder, S. R., Schooler, N. R., Wirshing, W. C., Umbricht, D., Baker, R. W., Wirshing, D. A., Safferman, A., Ganguli, R., McMeniman, M., et al. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.10.965 · Cited by 178
Meltzer, H. Y., Bobo, W. V., Roy, A., Jayathilake, K., Aygun, C., Elif, E. A., Yagcioglu, A., & Small, J. G. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0214 · Cited by 176
Høyberg, O. J., Fensbo, C., Lingjærde, O., Sloth‐Nielsen, M., Salvesen, I., & Remvig, J. (1993) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1993.tb03480.x · Cited by 176
Potkin, S. G., & Cohen, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1004 · Cited by 175
Emsley, R. A., Raniwalla, J., Bailey, P. J., & Jones, A. M. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00001 · Cited by 175
Daniel, D. G., Potkin, S. G., Reeves, K. R., Swift, R. H., & Harrigan, E. P. (2001) · Psychopharmacology · doi:10.1007/s002130000658 · Cited by 173
Effectiveness of Switching Antipsychotic Medications
Essock, S. M., Covell, N. H., Davis, S. M., Stroup, T. S., Rosenheck, R. A., & Lieberman, J. A. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.12.2090 · Cited by 172
Self-citationChlorpromazine versus placebo for schizophrenia
Adams, C. E., Awad, G. A., Rathbone, J., Thornley, B., & Soares-Weiser, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000284.pub3 · Cited by 171
Simpson, G. M., Glick, I. D., Weiden, P. J., Romano, S. J., & Siu, C. O. (2004) · American Journal of Psychiatry · doi:10.1176/ajp.161.10.1837 · Cited by 170
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens, J., Bech, P., Möller, H.-J., Bale, R., Fleurot, O., & Rein, W. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00075-x · Cited by 170
Self-citation
Cited by
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Galletly, C., Castle, D., Dark, F., Humberstone, V., Jablensky, A., Killackey, E., Kulkarni, J., McGorry, P., Nielssen, O., & Tran, N. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416641195 · Cited by 877
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Self-citationThe impact of environmental factors in severe psychiatric disorders
Schmitt, A., Malchow, B., Hasan, A., & Falkai, P. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00019 · Cited by 322
Self-citation
Metadata
- Authors
- Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 13
- Issue
- 5
- Pages
- 318-378
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2157369969
- Cited by
- 637
- References
- 529
- FWCI
- 22.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.